Fairytale ending? Mythic flags new approach to improving ADC performance 04-Jan-2022 By Jane Byrne December 2021 saw the launch of a new US based biotech, Mythic Therapeutics, with an oversubscribed Series B financing round of US$103m.
Novasep secures manufacturing deal with US biotech for ADC drug candidate 06-Jul-2021 By Jane Byrne Novasep has signed a manufacturing services agreement with Exelixis, an oncology-focused US biotechnology company, for the cGMP clinical production of XB002, a next-generation tissue factor-targeting antibody-drug conjugate (ADC).